Differential effects of fexofenadine on arachidonic acid metabolism in cultured human monocytes

Pharmacology

Volumn 76, Issue 1, 2005, Pages 40-45

  Juergens, Uwe R ^a,b   Darlath, Wilfried ^d   Stöber, Meinolf ^a   Racké, Kurt ^c   Tasci, Selcuk ^b   Gillissen, Adrian ^e   Vetter, Hans ^a  

^a Allergology and Sleep Medicine Medical Outpatient Clinic   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e Robert Koch Klinik   (Germany)

Author keywords

Allergic rhinitis; Antihistamine; Arachidonic acid; Fexofenadine

Indexed keywords

ARACHIDONIC ACID; FEXOFENADINE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; ZYMOSAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; BLOOD DONOR; CELL CULTURE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME IMMUNOASSAY; FATTY ACID METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; INHIBITION KINETICS; MONOCYTE; NORMAL HUMAN; NOSE CONGESTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; STATISTICAL SIGNIFICANCE;

ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; CELLS, CULTURED; DINOPROSTONE; HISTAMINE H1 ANTAGONISTS; HUMANS; LEUKOTRIENES; LIPOPOLYSACCHARIDES; MONOCYTES; TERFENADINE; ZYMOSAN;

EID: 28744451645     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089263     Document Type: Article

References (23)

1. Bousquet J, van Cauwenberge PV, Khaltaev N, Aria Workshop Group, World Health Organization: Allergie rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(suppl 5):S147-S334.
2. Gregory C, Cifaldi M, Tanner LA: Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care 1999;5:485-496.
3. Meltzer E, Nathan R, Selner J, Storms W: Quality of life and rhinitis symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaire. J Allergy Clin Immunol 1997;99:S815-S819.
4. Greaves M: Chronic urticaria. J Allergy Clin Immunol 2000;105:664-672.
5. White M, Kaliner M: Mediators of allergic rhinitis. J Allergy Clin Immunol 1992;90:699-704.
6. Naclerio R: Pathophysiology of perennial allergic rhinitis. Allergy 1997:52(suppl 36):7-13.
7. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289-297.
8. Druce H, Kaliner M: Allergic rhinitis. J Am Med Assoc 1988;259:260-263.
9. Busse W: The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996;26:868-879.
10. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J: Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-448.
11. Howarth P, Stern M, Roi L, Reynolds R, Bousquet JP: Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 mg and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:927-933.
12. van Cauwenberge P, Juniper EF: Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891-899.
13. Lombardo VT, Hodson E, Roberts JR, Kunicki TJ, Zimmerman TS, Ruggeri ZM: Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by monoclonal antibody. J Clin Invest 1985;76:1950-1958.
14. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL: Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatic patients before and after oral aspirin challenge. J Allergy Clin Immunol 1992;90:636-645.
15. McAdam BF, Mardini IA, Habib A, Burke A, Lawson JA, Kapoor S, Fitzgerald GA: Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000;105:1473-1482.
16. Allegra Prescribing Information. Revised 2003.
17. 4 production in vitro. Eur J Med Res 2004;9:365-370.
18. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ: Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-420.
19. Paolieri F, Battifora M, Riccio AM, Bertolini C, Cutolo M, Bloom M, Ciprandi G, Canonica GW, Bagnasco M: Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998;81:601-607.
20. 1 receptors. J Immunol 2001;266:4083-4091.
21. Gelfand EW, Cui ZH, Takeda K, Kanehiro A, Joetham A: Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 2002;110:85-95.
22. 1-receptor effects of antihistamines. Clin Exp Allergy 1999;29(suppl 3):39-48.
23. Holgate ST, Canonica GW, Simons FE, Taglialatela M, Tharp M, Timmerman H, Yanai K: Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33:1305-1324.